The DOI matches its Crossref record.
Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations
Abstract
This study assessed reproductive performance, fetal viability and teratogenicity in female mice exposed to cyclophosphamide across a timeline corresponding to different stages of follicle maturation. Pregnancies were established in female Balb/c mice 1-4 weeks after administration of a non-sterilizing dose of cyclophosphamide (75 mg/kg). Each mating group represented a different stage of follicular growth at the time of cyclophosphamide exposure. The number of corpora lutea, pregnancies and fetal resorptions were determined. Surviving fetuses were evaluated for gross malformations. Results indicated that conceptions attributable to follicles exposed to cyclophosphamide at a mature stage had a significantly lower number of implantation sites, 4.82 +/- 1.01 versus 8.27 +/- 0.81 in controls (P = 0.001) and a high resorption rate, 56% +/- 0.11 versus 34% +/- 0.07 in controls (P = 0.05). The proportion of corpora lutea in this group which resulted in viable fetuses was extremely low, 0.2 +/- 0.06 versus 0.51 +/- 0.07 in controls (P = 0.001). Malformation rate was more than 10 times higher in all treated groups (P < 0.05) and a particularly high incidence of 33% (P = 0.0014) was observed in conceptions attributable to oocytes exposed to cyclophosphamide at the earliest stages of follicle growth. With an extended interval between exposure and mating the malformation rate gradually decreased towards normal values in the 12th week group. This study suggests that the effect of cyclophosphamide on female gametes and subsequently on future reproduction is influenced by the stage of oocyte maturation at the time of exposure. Early fertilization post-chemotherapy can result in a high rate of pregnancy failure and high malformation rate. This should be taken into account when considering the use of oocyte retrieval, IVF and embryo cryopreservation in patients currently undergoing chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.09.013 · Cited by 753
Ovarian damage from chemotherapy and current approaches to its protection
Spears, N., Lopes, F., Stefansdottir, A., Rossi, V, De Felici, M., Anderson, R. A., & Klinger, F. G. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz027 · Cited by 657
How do chemotherapeutic agents damage the ovary?
Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H., & Spears, N. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms022 · Cited by 409
Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact
Bedoschi, G., Navarro, P. A., & Oktay, K. (2016) · Future Oncology · doi:10.2217/fon-2016-0176 · Cited by 356
Genetic and teratogenic effects of cancer treatments on gametes and embryos
Arnon, J., Meirow, D., Lewis-Roness, H., & Ornoy, A. (2001) · Human Reproduction Update · doi:10.1093/humupd/7.4.394 · Cited by 306
Self-citation
Metadata
- Authors
- Meirow, D., Epstein, M., Lewis, H., Nugent, D., & Gosden, R. G.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04
- Volume
- 16
- Issue
- 4
- Pages
- 632-637
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2001178179
- Cited by
- 229
- References
- 0
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. https://app.cochat.ai/papers/10.1093/humrep/16.4.632
- The paper
- Meirow, D., Epstein, M., Lewis, H., Nugent, D., & Gosden, R. G. (2001). Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Human Reproduction. https://doi.org/10.1093/humrep/16.4.632
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.